Skip to main content
SpringerLink
Log in

Cemiplimab may be cost effective as first-line therapy for advanced NSCLC in the USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Wang L, et al. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50. Advances in Therapy : 9 Jul 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01828-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cemiplimab may be cost effective as first-line therapy for advanced NSCLC in the USA. PharmacoEcon Outcomes News 883, 9 (2021). https://doi.org/10.1007/s40274-021-7880-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7880-z

Search

Navigation